Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Alx Oncology Holdings Inc.
Sponsor

Alx Oncology Holdings Inc.

United States 323 Allerton Avenue, 94080-4816, United States

About the sponsor

Clinical research in metastatic and unresectable recurrent HNSCC focuses on immunotherapy-based combinations and first-line treatment settings for advanced disease.

  • Pembrolizumab
  • Platinum-based chemotherapy
  • Objective response rate

The sponsor’s work in this area centers on treatment options for patients with advanced disease who have not yet received therapy for their metastatic or recurrent cancer.

About Specializations

Alx Oncology Holdings Inc. runs clinical trials in conditions such as Neoplasm malignant, Squamous cell carcinoma of head and neck, Squamous cell carcinoma, Head and neck cancer, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

5 clinical trials

Breast cancer metastatic

Recruiting

A Study of Evorpacept Combined with Trastuzumab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Alx Oncology Holdings Inc.

Gastric cancer

Not recruiting

Study of ALX148 with Trastuzumab, Ramucirumab, and Paclitaxel for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Alx Oncology Holdings Inc.

Neoplasm malignant+3

Not recruiting

Study of ALX148 and Pembrolizumab for Patients with Advanced Head and Neck Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Alx Oncology Holdings Inc.

Neoplasm malignant+3

Not recruiting

Study of ALX148, Pembrolizumab, and Chemotherapy for Patients with Advanced Head and Neck Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Alx Oncology Holdings Inc.

Myelodysplastic syndrome

Not recruiting

Study of ALX148 and Azacitidine for Untreated Higher Risk Myelodysplastic Syndrome Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ALX148
  • Sponsor:Alx Oncology Holdings Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.